Skip to content

ROLE OF ZINC IN TREATMENT OF ACUTE RESPIRATORY ILLNESS IN CHILDREN

ROLE OF ZINC AS AN ADJUVANT THERAPY IN ACUTE SEVERE PNEUMONIA IN CHILDREN OF AGE 2 MONTHS TO 2 YEARS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/09/046070
Enrollment
94
Registered
2022-09-30
Start date
Unknown
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J189- Pneumonia, unspecified organism

Interventions

Intervention1: Oral Zinc Supplementation: Children will be prescribed antibiotics and randomly allocated to receive 20 mg elemental zinc or placebo, in 2 doses per day to minimize adverse gastrointest

Sponsors

Vijayanagar Institute of Medical Sciences Ballari Karnataka
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All children aged 2 months to 2 years diagnosed as having acute severe pneumonia and hospitalized will be included in the study after obtaining written informed consent from either of the parents. Acute Severe Pneumonia is defined in the study as a respiratory rate of 50/min, accompanied with crepitations on auscultation and the presence of any one of the following danger signs: lethargy, inability to feed, chest indrawing, or central cyanosis.

Exclusion criteria

Exclusion criteria: Children will be excluded if they had a history of chronic cardiac or renal disease, illness severe enough to require ventilation, malnutrition severe enough to require immediate nutritional rehabilitation therapy, illness requiring hospitalization in the previous 21 days, or current zinc supplementation.

Design outcomes

Primary

MeasureTime frame
Duration of hospitalization, Duration of Severe Pneumonia, Duration of Pneumonia, Duration of nil-per-oral, Duration of Intravenous fluids, Duration of oxygen use, Treatment failure requiring 2 nd or 3 rd line drugs.Timepoint: Duration of hospitalization, Duration of Severe Pneumonia, Duration of Pneumonia, Duration of nil-per-oral, Duration of Intravenous fluids, Duration of oxygen use

Secondary

MeasureTime frame
Treatment failure requiring 2 nd or 3rd line drugs, Recovery timeTimepoint: Treatment failure requiring 2 nd or 3rd line drugs, Recovery time

Countries

India

Contacts

Public ContactSathiyanarayanan S

All India Institute of Medical Sciences (AIIMS), Mangalagiri

sathiya@aiimsmangalagiri.edu.in9597339969

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 5, 2026